|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT00993694 |
|
Date of registration:
|
09/10/2009 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
|
|
Scientific title:
|
Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia |
|
Date of first enrolment:
|
January 2009 |
|
Target sample size:
|
41 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00993694 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Adam J. Esbenshade, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Vanderbilt-Ingram Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS:
- Diagnosis of hematologic malignancy or aplastic anemia
- Treated within the past 15 years with dapsone prophylaxis during treatment of
primary disease
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Age minimum:
N/A
Age maximum:
18 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Myeloproliferative Disorders
|
|
Multiple Myeloma and Plasma Cell Neoplasm
|
|
Myelodysplastic/Myeloproliferative Neoplasms
|
|
Leukemia
|
|
Myelodysplastic Syndromes
|
|
Lymphoproliferative Disorder
|
|
Nonmalignant Neoplasm
|
|
Methemoglobinemia
|
|
Lymphoma
|
|
Intervention(s)
|
|
Procedure: assessment of therapy complications
|
|
Drug: dapsone
|
|
Other: medical chart review
|
|
Drug: chemotherapy
|
|
Primary Outcome(s)
|
|
Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years
|
|
Major risk factors for developing methemoglobinemia
|
|
Secondary ID(s)
|
|
P30CA068485
|
|
VU-VICC-PED-0916
|
|
CDR0000652603
|
|
IRB# 090009
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|